CMND

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical development considerations for psychedelic drugs, including MDMA TEL AVIV, Israel, Aug. 24, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its  subsidiary, NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, ,today announced that its ongoing collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind") has advanced wi

U.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration with Neurothera Labs Inc. as the FDA  introduces a dedicated regulatory structure for psychedelic drug development, including MDMA Vancouver, Canada, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biopharmaceutical  company   advancing non-hallucinogenic, psychedelic-derived neuroplastogens  for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders, including AUD,  today announced  an advancement of its IP portfolio with the publication in the United States of its pat

Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND‑100 in patients with Alcohol Use Disorder (AUD) - a key milestone in the progression of the Company’s clinical development program. Vancouver, Canada, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, such as addictions and weight-loss, recently  announced that its independent DSMB has unanimously approved advancin

SCHEDULE 13G/A - Clearmind Medicine Inc. (0001892500) (Subject)

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND, FSE: CWY0)) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, such as addictions and weight-loss, today announced positive permeation study results from its ongoing intranasal MEAI development program. The new findings confirm that the enhanced nasal residence time previously demonstrated with the proprietary intranasal MEAI formulation does not compromise the permeation characteristics of Clearmind's proprietary M

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND‑100 in patients with Alcohol Use Disorder (AUD) - a key milestone in the progression of the Company’s clinical development program. Vancouver, Canada, Aug. 06, 2026 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company"), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for AUD, addictions, and weight management, today announced that its independent DSMB has unanimously approved advancing the Company’s ongoing FDA-regulated Phase I/II clinical trial to parts B and C (the two of the rem

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered into a non-binding Letter of Intent ("LOI") to acquire 51% stake in a leading intelligent EV (electric vehicles) wireless charging solutions for automated parking systems and autonomous mobile platforms company (the "Acquired Company"). The Acquired Company develops intelligent wireless charging solutions for automated

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, July 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder (AUD), addictions, and weight management, today announced positive safety results from Part A of its ongoing FDA-regulated Phase I/II clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). Clearmind reported that all 24 participants enrolled across four ascending-dose cohorts successfully completed treatment as planned per-protocol, reinforcing the strength of its proprietary drug candid

Vancouver, Canada, July 28, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ("Clearmind" or "Company") (NASDAQ:CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder ("AUD"), addiction, and weight management, recently announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of AUD. All 24 participants across cohorts 1 through 4 have successfully completed treatment according to the study protocol. The Company is currently assessing the dataset and, assuming results remain favorable, intends to initiate the n

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. ("Clearmind") (NASDAQ:CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder ("AUD"), addiction, and weight management, today announced the filing of a patent application with the Hong Kong Patent Office for innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder ("PTSD") and other mental health disorders. The Hong Kong patent application forms part of Clearmind’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem ("Yissum"). Under t

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, today noted the significant regulatory and inter-agency developments this week supporting the development of innovative treatments for serious neuropsychiatric and addiction disorders. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated: "At a time when patients in the veterans community and the general population have too few treatment options for intractable neuropsychiatric and addiction disorders, we are grateful that Secreta

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biotechnology company pioneering non‑hallucinogenic neuroplastogen‑derived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, announced today compelling ex vivo mucoadhesion results for its intranasal formulation of MEAI (5‑Methoxy‑2‑aminoindane). Leveraging a nasal drug‑delivery system, the new formulation demonstrated markedly improved nasal residence characteristics compared with a standard MEAI solution. Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind’s strategy

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine’s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder Vancouver, Canada, July 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today provides key insights from its June 10 webinar, "Inside MEAI," during which the Company’s CEO and the leading investigators of the Company’s ongoing first-in-human clinical trial of C

6-K - Clearmind Medicine Inc. (0001892500) (Filer)

Vancouver, Canada, July 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage a biotech company developing novel, non-hallucinogenic, next-generation, neuroplastogen-derived therapeutics to solve major under-treated mental health problems, with a focus on Alcohol Use Disorder and other addiction related diagnoses, today announced that it has submitted a formal response to the U.S. Department of Health and Human Services (HHS) Request for Information (RFI) about MEAI’s potential as an innovative, empirically-evidenced intervention for the treatment of addiction. Clearmind proposes an innovative model to enable inexpensive, scalable, and clinically effective

6-K - Clearmind Medicine Inc. (0001892500) (Filer)